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Abstract
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Neuropoietin (NP) is a member of the gp130 cytokine family that is closely related to
cardiotrophin-1(CT-1) and shares functional and structural features with other family members,
including ciliary neurotrophic factor (CNTF) and cardiotrophin-like cytokine (CLC). Studies have
shown that NP can play a role in the development of the nervous system, as well as affect
adipogenesis and fat cell function. However, the signaling mechanisms utilized by NP in
adipocytes have not been examined. In our present studies, we demonstrate that NP-induced
activation of STAT3 tyrosine phosphorylation is independent of leukemia inhibitory factor
receptor (LIFR) phosphorylation and degradation. Although it is widely accepted that NP signals
via the LIFR, our studies reveal that NP results in phosphorylation of gp130, but not LIFR. These
observations suggest that the profound effects that NP has on adipocytes are not mediated via
LIFR signaling.
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Introduction
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Neuropoietin (NP) is a gp130 cytokine that was characterized as a regulator of central
nervous system development in mice that could modulate motor neuron survival in vitro [1].
NP was shown to be highly expressed in mouse embryonic neuroepithelia [1] and has been
shown to be capable of inducing neuroepithelial cells to differentiate into astrocytes [2].
Though the studies of NP action had been limited to the nervous system, studies from our
laboratory have also examined the effects of NP in adipocytes [3]. Our data indicate that NP
is a potent activator of Signal Transducer and Activator of Transcription (STAT) 3 and
MAPK (ERKs 1 and 2) in both 3T3-L1 adipocytes in vitro and adipose tissue in vivo.
Moreover, NP was shown to inhibit adipogenesis and have profound effects on insulin
signaling both in vitro and in vivo.
Though all members of the gp130 cytokine family utilize glycoprotein 130 (gp130) as a
common signal transducer in the receptor complex for signaling, these cytokines exert
differential effects on multiple tissues. This specificity can be partially attributed to the
presence of other receptor components that are required for activation, including the
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leukemia inhibitory factor (LIF) receptor and the cytokine's specific α receptor. A common
feature of many gp130 cytokines is their shared use of not only gp130, but also of LIFR
proteins as components of their receptor complex. Numerous studies have shown gp130
cytokine signaling results in LIFR activation (reviewed in [4]), which is followed by LIFR
internalization and degradation in various cell types, including adipocytes [5-7]. It is also
well established that gp130 cytokines induce the tyrosine phosphorylation of their recruited
signal transducer receptors, including the LIFR, upon ligand binding (reviewed in [4].
NP has been reported to utilize a membrane receptor complex consisting of ciliary
neurotrophic factor (CNTF) receptor α, gp130, and the LIF receptor for signal transduction
[1]. Our novel observations in this study demonstrate that NP does not induce LIFR
activation, as judged by both LIFR degradation and LIFR tyrosine phosphorylation. In
addition, NP does not induce the activation of OSMRβ, a receptor used by oncostatin (OSM)
that has substantial structural homology to the LIFR [8]. Overall, these studies demonstrate
that STAT3 activation induced by NP in adipocytes is not mediated via LIFR signaling.

Materials and Methods
Materials
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Dulbecco's Modified Eagle's Media (DMEM) was purchased from Sigma. Bovine and fetal
bovine (FBS) sera were purchased from Hyclone. Mouse recombinant NP, mouse
recombinant CT-1, mouse recombinant OSM, and mouse recombinant OSMRβ antibodies
were all purchased from R&D Systems. Recombinant human OSM was purchased from
Invitrogen, and mouse recombinant LIF was purchased from BD Transduction.
Cycloheximide was purchased from Sigma, and 4G10 was purchased from Millipore
(previously Upstate). Phospho-specific STAT3 (Y705) monoclonal antibody was purchased
from BD Transduction. Both the gp130 and LIFR polyclonal antibodies were purchased
from Santa Cruz. Protein-A agarose was purchased from Repligen Corporation.
Nitrocellulose was purchased from Bio-Rad. The BCA kit and the enhanced
chemiluminescence kit were purchased from Pierce. Horseradish peroxidase (HRP)conjugated secondary antibodies were purchased from Jackson ImmunoResearch
Laboratories.
Cell Culture
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Murine 3T3-L1 preadipocytes were plated and grown to 2 days post-confluence in DMEM
containing 10% bovine serum. Medium was changed every 48 h. Cells were induced to
differentiate by changing the medium to DMEM containing 10% fetal bovine serum (FBS),
0.5 mM 3-isobutylmethylxanthine, 1 μM dexamethasone, and 1.7 μM insulin (MDI). After
48 h, this medium was replaced with DMEM supplemented with 10% FBS, and cells were
maintained in this medium until utilized for experimentation.
Preparation of Whole Cell Extracts
Cell monolayers of 3T3-L1 adipocytes were harvested in a non-denaturing buffer containing
150 mM NaCl, 10 mM Tris pH 7.4, 1mM EGTA, 1mM EDTA, 1% Triton-X 100, 0.5%
Igepal CA-630, 1 μM phenylmethylsulfonyl fluoride (PMSF), 1 μM pepstatin, 50 trypsin
inhibitory milliunits of aprotinin, 10 μM leupeptin, and 2 mM sodium vanadate and frozen.
Next, the samples were thawed and centrifuged at 14,000 × g at 4°C for 10 minutes.
Supernatants containing whole cell extracts were analyzed for protein content using a BCA
kit according to the manufacturer's instructions.
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Immunoprecipitations of LIFR, OSMRβ, or gp130 from adipocyte extracts
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Cell monolayers of 3T3-L1 adipocytes were harvested under non-denaturing conditions
following cytokine treatment, and the protein content was determined as described above.
The protein extracts were preincubated with protein-A agarose, and the resulting
supernatants were then incubated with 5 μg of either the LIFR, OSMRβ, or gp130 antibody
for 2 hours at 4°C. Protein-A agarose was added to the mixture, and the samples were
incubated for an additional hour. Bound LIFR, OSMRβ, or gp130 and any associated
proteins were isolated by pelleting this mixture. The pellets were rinsed twice with
phosphate-buffered saline (PBS), and bound proteins were eluted from the agarose by
incubation at 100°C for 10 minutes after the addition of Laemmli sample buffer. These
samples were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis and analyzed by Western blotting with 4G10 antibody.
Gel Electrophoresis and Western Blot Analysis
Proteins were separated in 7.5% polyacrylamide (acrylamide from Nationl Diagnostics) gels
containing sodium dodecyl sulfate (SDS) according to Laemmli [9] and transferred to
nitrocellulose membrane in 25 mM Tris, 192 mM glycine, and 20% methanol. Following
transfer, the membrane was blocked overnight in 4% milk at 4°C. Results were visualized
with horseradish peroxidase (HRP)-conjugated secondary antibodies and enhanced
chemiluminescence.
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Results
Previous studies demonstrated that several gp130 cytokines, notably LIF, CT-1, and hOSM,
induce STAT3 tyrosine phosphorylation that is accompanied by LIFR degradation in
adipocytes [5]. Since NP activates STAT3 in adipocytes in vitro and in vivo [3], we
examined the ability of this gp130 cytokine to modulate LIFR degradation in adipocytes.
Fully differentiated 3T3-L1 adipocytes were treated with cycloheximide (CH) in the
presence or absence of LIF or NP. As shown in Figure 1, the expression levels of LIFR in
adipocytes treated with LIF dramatically decreased within 1-hr as previously reported [5].
However, NP treatment did not cause a substantial decrease in LIFR degradation. The
efficacy of both LIF and NP was shown by the activation of STAT3 Tyr705. We also
observed that NP failed to induce LIFR degradation in differentiated OP9 mouse stromal
cells (data not shown), a newly characterized adipocyte cell culture model [10].
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It is well established that gp130 cytokines induce the tyrosine phosphorylation of their
recruited signal transducer receptors, including the LIFR, upon ligand binding (reviewed in
[4]). Since our results indicated that NP did not induce LIFR degradation, we examined the
ability of NP to induce the tyrosine phosphorylation of the LIFR, since NP has been reported
to signal via the LIFR [1]. The ability of gp130 cytokines to phosphorylate the LIFR was
examined by immunoprecipitating LIFR from whole cell extracts and immunoblotting with
4G10, an anti-phosphotyrosine antibody. As shown in Figure 2A, both LIF and hOSM, but
not NP, induced the phosphorylation of the LIFR, and this effect was not attributed to
differences in LIFR expression. The lack of LIFR phosphorylation following mOSM
stimulation supports previous studies that revealed an alternative receptor complex in
murine cells for this cytokine [11]. The efficacy of each cytokine was shown by the
activation of STAT3 Tyr705. These surprising observations indicated that although
previously reported to signal via the LIFR [1], NP does not induce phosphorylation of the
LIFR. Hence, we examined the ability of NP to activate oncostatin M receptor β (OSMRβ),
which is similar in structure to the LIFR and is utilized by mOSM for signal transduction
[8]. The results in Figure 2B demonstrate that mOSM, but not NP, induced the tyrosine
phosphorylation of the OSMRβ. The efficacy of each cytokine was shown by the activation
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of STAT3 Tyr705. Although NP did not induce LIFR or OSMRβ activation, the results in
Figure 2C demonstrate that NP was capable of inducing gp130 tyrosine phosphorylation in a
manner equivalent to CT-1, LIF, and mOSM.

Discussion
Although NP was originally characterized as a cytokine that utilized the LIFR for signal
transduction [1], our novel data indicate that NP does not induce the phosphorylation or
degradation of the LIFR (Figures 1 and 2A) in the same manner as other gp130 cytokines in
adipocytes. Although NP induces gp130 and STAT3 tyrosine phosphorylation, this occurs in
a manner that is unaccompanied by the activation of either the LIFR or OSMRβ. While
several lines of evidence support significant roles for NP in neuronal development [1;2], the
actions of NP in other tissues have not been studied. However, NP has important functions
in adipose tissue, including the ability to modulate fat cell development and insulin
sensitivity [3]. Despite these significant effects, the mechanisms underlying NP signal
transduction action in adipocytes have not been previously examined.
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Gp130 is the shared subunit in each respective receptor complex of the gp130 cytokines, but
additional receptor components can be responsible for specific actions in particular cell
types. Therefore, understanding the signal transducing complex for each cytokine is critical.
It is known that NP activates STAT3, as do other gp130 cytokines, in both neuroepithelial
cells and adipocytes. As a result of its initial characterization in the nervous system, it is
largely accepted that NP-induced STAT3 activation is mediated by a receptor complex
composed of LIFR, CNTFRα, and gp130 [1]. However, our investigations show conflicting
evidence for LIFR activation by NP in adipocytes. We postulate that NP action on
adipocytes is independent of LIFR activation. Although the complete identify of the NP
receptor complex in adipocytes has not been characterized, we have shown that gp130, but
not LIFR or OSMRβ (Figure 2) plays a role in NP signaling in adipocytes. Further studies
are necessary to determine the complex signaling mechanisms of NP in adipocytes, as well
other cell types.
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Fig. 1. NP does not induce LIFR degradation

Fully differentiated 3T3-L1 adipocytes were treated with either 1 nM LIF or 1 nM NP in the
presence of 5 μM cycloheximide (CH). Whole cell extracts were prepared from adipocytes
that were untreated (0) or treated at the indicated times. 125 μg of extract was separated by
SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. This is a
representative experiment independently performed three times.
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Fig. 2. NP treatment induces the tyrosine phosphorylation of gp130, but not LIFR or OSMRβ in
3T3-L1 adipocytes

(A) Whole cell extracts were isolated from fully differentated 3T3-L1 adipocytes that were
harvested after vehicle treatment (CTL) or an acute (6 min.) treatment with a 1 nM of either
CT-1, LIF, mOSM, hOSM, or NP. Each extract was subjected to immunoprecipitation (IP)
with an antibody directed against the LIFR (A), OSMRβ (B), or gp130 (C) and Western
blotting analysis with 4G10, an anti-phosphotyrosine antibody. Either 700 μg (A), 600 μg
(B), or 650 μg (C) of protein was used for IP, and 90 μg of protein was used for Western
blotting. For each IP experiment, a mock control that contained everything but cell extract
was used. Each figure is a representative experiment independently performed four times.
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